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ABSTRACT 
Objective: The present study was aimed to develop a rapid, specific and sensitive method based on high performance liquid chromatographic 
method was developed for the determination of telmisartan using indapamide as an internal standard.  
Methods: The utilization of single step protein precipitation method using methanol as a precipitating agent becomes suitable for analysis of a large 
number of samples. The developed method was validated as per US-FDA guidelines for telmisartan in human plasma. 
Result: An isocratic separation was achieved using Hibar C18
Conclusion: The developed analytical method was found to be rapid, single step, plasma preparation coupled with the simple high-performance 
liquid chromatography coupled with UV detection (HPLC–UV) isocratic chromatographic apparatus makes the method cost-effective and suitable 
for analysis of a large number of samples. 
 (250 x 4.6 mm, 5 μm) column using 10 mmol ammonium formate solution (pH 4.0)–
methanol (70:30, v/v) as the mobile phase. Detection was carried out at 275 nm. The method was validated over the range of 0.1–1.5 µg/ml in 
human plasma with a regression analysis of 0.996. The percentage recovery of the present method was found to be 94.0–99.2 %.  
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benzi-midazole-1-yl] methyl] biphenyl-2-carboxylic acid is a 
selective angiotensin II receptor blocker used for the treatment of 
hypertension and heart failure [1,2]. They block the vasoconstrictor 
and aldosterone-secreting effects of angiotensin II by blocking the 
binding of angiotensin II to the AT1 receptor in vascular smooth 
muscles and adrenal glands. It is a poorly water-soluble drug and its 
bioavailability is 42-58 % and are highly bound to plasma proteins 
(>99. 5 %) and has a half-life of 24 h. 
Detailed literature survey for telmisartan revealed that, two high 
performance liquid chromatography (HPLC) methods for 
determination of telmisartan and hydrochlorothiazide in 
pharmaceutical preparation [3,4] and a liquid chromatographic-
tandem mass spectrometric method (LC-MS/MS) for the simultaneous 
quantitation of telmisartan and hydrochlorothiazide in human plasma 
[5] was also reported by which the method is tedious in samples 
preparation, relied on tedious liquid-liquid extraction procedure, used 
complicated gradient elution and expensive equipment. Therefore, it 
was desirable to develop a simple, accurate, cheap and fast procedure 
that could be applied for the determination of telmisartan in human 
plasma. Hence a novel, fast and simple protein precipitation method 
was involved in determining telmisartan in human plasma prior to 
reverse phase-HPLC detection. The present work presents a simple, 
rapid and sensitive economical method for determination of 
telmisartan in human plasma compared to the published methods. 
MATERIALS AND METHODS 
Chemicals and reagents 
Telmisartan and indapamide were received as a gift sample. HPLC 
grade methanol and acetonitrile were procured from Rankem Fine 
Chemical Limited and Water of HPLC grade from Milli-Q RO system 
(Millipore, Bedford, USA) were used. Ammonium formate and formic 
acid used were of analytical grade.  
The ammonium formate buffer (10 mmol) was prepared by 
dissolving 0.63 g in a litre of distilled water and pH was adjusted to 
4.0 using formic acid and 0.1 N NaOH. Drug-free human plasma was 
obtained from the hospital blood bank.  
Calibration standards and quality control samples in human 
plasma  
Telmisartan and indapamide stock solutions were prepared by 
dissolving in methanol by dissolving each, to produce a concentration 
of 1 mg/ml. Further, dilutions were made with methanol to produce 
the working calibration standards ranging from 0.1–1.5 µg/ml using 
0.8 µg/ml of internal standard (indapamide).  
Quality control samples were prepared separately at three different 
concentration levels of 0.1, 0.7 and 1.3 µg/ml as low medium and 
high respectively.  
Preparation of plasma sample 
The stored plasma samples were allowed to thaw at room 
temperature and were centrifuged before analysis. An aliquot of 0.5 
ml of centrifuged plasma was pipetted into an eppendorf tube, and 
methanol (1.5 ml) was added to which each 0.1 ml of telmisartan 
and IS was added. The mixture was vortexed, and after standing for 
10 min at room temperature, the mixture was centrifuged at 5000 
rpm for 10 min. The supernatant was carefully transferred into vials 
and injected into HPLC system.  
Liquid chromatography–UV spectrometry 
The samples were analyzed using high-performance liquid 
chromatography (Shimadzu gradient HPLC system) equipped with a 
solvent delivery system (Model-LC-10 AT-VP), Rheodyne injector 
(Model-7725i with 20μl loop), and UV detector (Model-SPD M-10A 
VP). The data acquisition was performed on Class VP data station 
software. Separation and quantification were made on Hibar C18 
(250 x 4.6 mm, 5 μm) column were used for method development 
and validation at ambient temperature (25 °C). In this current 
method, the separation was achieved using a mobile phase 
composed of 10 mmol ammonium formate solution (pH 4.0)–
methanol (70:30, v/v). The flow rate was 1 ml/min and detection at 
275 nm with an injection volume of 20 µl. 
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The method was validated for selectivity, matrix effect, precision, 
accuracy, linearity, sensitivity, and stability as per the USFDA 
guidelines for the validation of bioanalytical method [6].  
The Selectivity and specificity is the ability of an analytical method 
to differentiate and quantify the analyte in the presence of other 
components in the sample. The selectivity of this method was 
performed by analyzing six different concentrations of blank plasma 
samples to analyze the endogenous interference at the retention 
time of telmisartan and IS at lower quantitation limit (LLOQ). 
The presence of endogenous compounds in blood-derived products, 
it is necessary to evaluate the ion suppression or enhancement 
caused by matrix component leading to inaccurate results by 
comparing spiked quality control samples (LQC, MQC, and HQC).  
Linearity was evaluated using the average of six determinations at 
eight concentration levels covering the range of 0.1–1.5 µg/ml. For 
precision and accuracy studies, samples of three concentration 
levels at six replicates were prepared as low (LQC), medium (MQC) 
and high (MQC) quality controls, corresponding to 0.1, 0.7, 1.3 µg/ml 
respectively for telmisartan. The precision of the method was 
evaluated by intra-day, and inter-day precision studies and percent 
relative standard deviation (% RSD) of the regressed concentration 
was used to report precision. The accuracy of the method was 
determined by regression concentration represented as a 
percentage of the nominal concentration. 
The stabilities if telmisartan in the biological matrix and working 
solutions at different storage conditions were evaluated as follows 
and the results were expressed as percentage recoveries. QC 
samples were injected at six replicates in the same matrix of the 
study samples for freeze-thaw (3 cycles), short-term (room 
temperature), long-term (-20 °C), benchtop stability and stability 
samples (room temperature). Results for the stability samples 
should be within the 15 % of nominal concentration for QC samples. 
The sensitivity of the method was evaluated by the detection limit 
(signal-to-noise ratio of 3:1) and the quantitation limit (signal-to-
noise ratio of 10:1) 
RESULTS AND DISCUSSION 
To obtain the best chromatographic condition, different columns 
and mobile phases with different pH and strength were used to test 
the selectivity and sensitivity in short run time.  
The best chromatographic condition takes place on Hibar C18
 
 (250 x 
4.6 mm, 5 μm) column at ambient temperature (25 °C) using mobile 
phase 10 mmol ammonium formate solution (pH 4.0)–methanol 
(70:30, v/v). The flow rate was 1 ml/min and detection at 275 nm 
with an injection volume of 20 µl (fig. 1). 
 




The linearity of the method was evaluated by duplication 
determinations at different concentration levels ranging from 0.1–
1.5 µg/ml for telmisartan. A calibration curve was found to be linear 
with a regression coefficient (>0.99) and the intercept value 
summarized in table 1. 
Accuracy and precision 
Accuracy and precision of the method were evaluated by calculating 
the intra-day and inter-day precision at three different QC levels of 
six replicates. The mean accuracy level was determined by 
percentage nominal concentration 94.0 % to 99.2 % (intraday) and 
90.0 % to 93.8 % (interday) for telmisartan. The mean precision 
level was found to be within limits (≤ 15 %). The results indicate 
that the method developed was precise and accurate for the 
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analysis. The intraday and interday precision and accuracy results are summarized in table 2. 
  
Table 1: Assay parameters and regression characteristics determined by the proposed method 
Parameters Telmisartan 
Linearity range (µg/ml)* 0.1–1.5 
Detection limit (µg/ml) 0.04 
Quantitation limit (µg/ml) 0.1 
Slope (b) 1.3879 
SD of slope 0.001 
Intercept (a) 0.1612 
Correlation coefficient (r)  0.996 
Data given in this table is presented as mean, n=3, SD: standard deviation, regression equation: A = a+bc, where A is the absorbance, a is the 
intercept, b is the slope and c is the concentration. 
  
Table 2: Precision results of the proposed method 
QC Levels Added concentration (µg/ml) Conc. found 
(mean±SD) 
Intra-day recovery (%)±RSD 
(%) 
Inter-day recovery (%)±RSD (%) 
LQC 0.1 0.094±0.003 94.0±3.835 90.0±4.175 
MQC 0.7 0.673±0.020 96.1±3.091 92.0±4.947 
HQC 1.3 1.290±0.010 99.2±0.775 93.8±4.789 
Data given in this table is presented as mean, n=3, SD: standard deviation, RSD: relative standard deviation.  
 
Stability 
It is necessary to check the integrity of the drug during storage and 
analysis. Three QC levels were calculated at six replicates for freeze-
thaw, short-term, long-term and stability samples table 3. The 
results showed that the human samples containing telmisartan can 
be handled under normal laboratory conditions without any 
significant stability issues. 
 
Table 3: Summary of stability testing of telmisartan in human plasma under various conditions 
Parameters QC levels 
LQC MQC HQC 
(a) Three free-thaw cycles    
 Mean 0.096 0.683 1.276 
 SD 0.001 0.005 0.005 
 RSD 1.041 0.844 0.452 
(b) Benchtop stability    
 Mean 0.094 0.666 1.250 
 SD 0.001 0.005 0.010 
 RSD 1.219 0.866 0.800 
(c) Short term stability (room temp.)    
 Mean 0.090 0.630 1.220 
 SD 0.001 0.020 0.020 
 RSD 1.690 3.174 1.639 
(d) Long-term (-20 °C/2 w)    
 Mean 0.087 0.593 1.193 
 SD 0.002 0.015 0.015 
 RSD 2.298 2.574 1.280 
Data given in this table is presented as mean, n=3, SD: standard deviation, RSD: relative standard deviation, LQC: low-quality control, MQC: middle-
quality control, HQC: high-quality control. 
 
Sensitivity  
The limit of detection for this method was found to be the lowest 
limit detected for the drug telmisartan at 0.04 µg/ml based on the 
signal-to-noise ratio 3:1. Due to the increase in the sensitivity of the 
method, quantification was done at 0.1 µg/ml. This method found to 
have a high percentage recovery at low concentration at an 
acceptable limit. 
Robustness 
The proposed HPLC method showed ruggedness when deliberate 
changes in the organic strength (±2.0 %) and the pH (±0.2 unit) of 
the mobile phase were the retention time of the peak was not 
significantly affected (±0.03 min). 
System suitability studies 
The resolution, number of theoretical plates, and peak asymmetry 
were calculated for the working solutions. The values obtained 
demonstrated the suitability of the system for the analysis of 
telmisartan in human plasma.  
In order to develop a simple and suitable RP-HPLC method for the 
estimation of telmisartan, different buffer ratios at different flow rate 
were applied for its estimation in human plasma. The previously 
reported method was found to be costly due to the use of highly 
sophisticated instruments liquid chromatography and tandem mass 
spectrometry (LC-MS/MS) and the method was found to be tedious 
due to the use of liquid-liquid extraction method using diethyl ether-
dichloromethane (60:40, v/v) as extraction solvent [5] but the present 
study involves the use of simple precipitation extraction method 
which produced a high recovery after detecting using RP-HPLC 
instrument. Few HPLC methods were reported for the estimation of 
telmisartan in formulation using RP-HPLC methods but the method 
were found to be not much sensitive for the detection of telmisartan in 
biological sources due to their detection and quantitation limit [3, 4], 
whereas in the present method telmisartan was detected and 
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quantified at 0.04 and 0.1 µg/ml, respectively which indicated that the 
method was sensitive, and can detect and quantify lower level of 
telmisartan in human plasma. Linearity range was from 0.1 to 1.5 
µg/ml with a regression coefficient of 0.996 indicating that at this 
concentration range telmisartan was highly linear.  
CONCLUSION 
The developed method was simple, accurate, and with the utilization 
of proteins precipitation technique, the method was found to be 
economical and simple rather than the previously published methods 
which are tedious. The rapid, single step, plasma preparation coupled 
with the simple HPLC–UV isocratic chromatographic apparatus makes 
the method cost-effective and suitable for analysis of a large number of 
samples. Due to the sensitivity of the developed method, it can be 
applied to the monitoring of plasma levels in the analysis of drug in 
preclinical and clinical pharmacokinetic studies. All the parameters 
and results were found within the acceptance limit as given in the 
validation protocol.  
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